Navigation Links
Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
Date:4/18/2011

ST. PAUL, Minn., April 18, 2011 /PRNewswire/ -- A letter sent by a commercial insurer to health care providers notifying them of potentially unsafe drug use when combining anti-clotting drug clopidogrel (Plavix®) with a proton pump inhibitor (PPI), showed a significant reduction in the number of members combining the drugs, according to a new study by pharmacy benefit management thought leader Prime Therapeutics (Prime). Details of the study will be presented on April 29th at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn.

Recent data has shown the use of some PPIs, commonly prescribed to reduce gastric acid production, in combination with clopidogrel, an antiplatelet medication used to prevent stroke and heart attack, can increase a person's risk for clopidogrel failure and a subsequent cardiac event. Current guidelines suggest providers re-evaluate the need for PPI therapy in patients taking clopidogrel and consider recommending another type of heartburn medication as an alternative treatment.

Researchers from Prime and one of its Blue Cross and Blue Shield clients used a retrospective drug utilization review to analyze claims data from a 1.3 million member commercial insurer. From this, researchers determined 1,316 members were actively combining clopidogrel with a PPI. A letter was then sent to health care providers alerting them of the potentially unsafe drug use and requesting the provider re-evaluate the need for PPI therapy in their patients. The study also tracked a control group of 2,740 patients who met intervention criteria but whose providers did not receive a letter.

At 180 days post-letter, actively enrolled members in both groups were assessed for the presence of a PPI, clopidogrel, or both. This analysis showed a significant absolute 7.5 percentage point reduction in the number of members who were combining PPIs and clopidogrel when they received the letter, compared to the control group.

"When patients or physicians are unaware of how drugs can react with one another they are potentially putting themselves at risk for greater harm and health complications," said Patrick Gleason, PharmD, Director of Clinical Outcomes Assessment for Prime. "This study shows that insurers, in partnership with pharmacy benefit managers, can increase member safety using simple and cost-effective tactics to significantly reduce the incidence of concurrent clopidogrel and PPI therapy and ensure patients continue to receive safe, high-quality care."

The published study abstract can be found in the Journal of Managed Care Pharmacy 2011;17(3):254-255 at http://www.amcp.org/amcp.ark?c=jmcp&sc=articles&year=2011&volume=17&issue=3.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Venture Construction ... Classic Tournament held on June 20th at the Woodmont Country Club at 1201 ... Wings, an organization dedicated to helping service members that have been wounded in battle ...
Breaking Medicine News(10 mins):